Aspira Women’s Health to Present at The Cancer Advocacy Group of Louisiana’s 3rd Annual NeauxCancer Conference
AUSTIN, Texas, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of
gynecologic disease diagnostic tools, today announced that management will present a corporate overview at The Cancer Advocacy Group of Louisiana’s 3rd Annual NeauxCancer Conference
taking place in New Orleans, Louisiana on February 29 to March 2, 2024. Management will be available for one-on-one meetings with investors who are registered for the conference.
Presentation Details: | |
Date: | Friday, March 1, 2024 |
Time: | 9:30 am CST / 10:30 am EST |
Webcast: | Click HERE to view the presentation |
Registration: | Click HERE to register and attend the conference |
About CAGLA
The Cancer Advocacy Group of Louisiana, Inc. (CAGLA) is a grassroots, non-profit advocacy organization committed to enhancing cancer care and research in Louisiana. The NeauxCancer Conference is an
annual multi-day, multi-track CME/CE conference that attracts over 400 leaders in oncology, including medical oncologists, cancer surgeons, radiation oncologists, as well as advanced practice
providers, medical trainees, nurses, pharmacists, and other healthcare professionals. The conference offers a wide variety of multi-disciplinary didactic sessions and expert panels focused on the
advanced management of cancer patients, including the intersection of new and emerging therapies, novel surgical approaches, radiation oncology, target therapies immunotherapies, and the
application of precision medicine. This year’s conference features 8-10 dynamic companies in a new investment track providing an opportunity to connect with attendees and investment advisors in the
Gulf South.
About Aspira Women’s Health Inc.
Aspira Women’s Health Inc. is dedicated to the discovery, development, and commercialization of noninvasive, AI-powered tests to aid in the diagnosis of gynecologic diseases.
Lesen Sie auch
OvaWatch and Ova1Plus are offered to clinicians as OvaSuite℠. Together, they provide the only comprehensive portfolio of blood tests to aid in the detection of ovarian cancer for the 1.2+ million American women diagnosed with an adnexal mass each year. OvaWatch provides a negative predictive value of 99% and is used to assess ovarian cancer risk for women where initial clinical assessment indicates the mass is indeterminate or benign, and thus surgery may be premature or unnecessary. Ova1Plus is comprised of two FDA-cleared tests, Ova1 and Overa, to assess the risk of ovarian malignancy in women planned for surgery.